Get the Stockscreener App
7.74
3.85%
-0.31
After Hours:
7.70
-0.04
-0.52%
Immunitybio Inc stock is traded at $7.74, with a volume of 21.45M.
It is down -3.85% in the last 24 hours and down -4.44% over the past month.
ImmunityBio Inc is a biotechnology company focused on developing and commercializing next-generation immunotherapies designed to activate the patient's immune system and provide durable protection against cancer and infectious diseases. Its approach harnesses both the adaptive and innate immune systems with the Cancer BioShield platform. The platform is built around the proprietary IL-15 superagonist ANKTIVA (nogapendekin alfa inbakicept) and is supported by a portfolio that includes adenovirus-vectored vaccines, NK-cell therapies, and additional immunomodulators. The company operates in the United States and Europe, with the majority of its revenue coming from the United States.
See More
Previous Close:
$8.05
Open:
$7.87
24h Volume:
21.45M
Relative Volume:
0.88
Market Cap:
$8.11B
Revenue:
$113.29M
Net Income/Loss:
$-351.47M
P/E Ratio:
-19.86
EPS:
-0.3898
Net Cash Flow:
$-309.19M
1W Performance:
-5.03%
1M Performance:
-4.44%
6M Performance:
+272.12%
1Y Performance:
+192.08%
1-Day Range:
$7.26
$7.90
1-Week Range:
$7.26
$8.64
52-Week Range:
$1.95
$12.43
Immunitybio Inc Stock (IBRX) Company Profile
Name
Immunitybio Inc
Sector
Industry
Phone
(844) 696-5235
Address
3530 JOHN HOPKINS COURT, SAN DIEGO
Compare IBRX vs VRTX, REGN, ARGX, ALNY, RVMD
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
IBRX
Immunitybio Inc
|
7.74 | 8.43B | 113.29M | -351.47M | -309.19M | -0.3898 |
VRTX
Vertex Pharmaceuticals Inc
|
433.54 | 109.25B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
642.59 | 68.12B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
816.22 | 50.01B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
300.51 | 39.85B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
153.73 | 31.96B | 742.00K | -1.37B | -1.07B | -7.0731 |
Immunitybio Inc Stock (IBRX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Mar-12-26 | Resumed | BTIG Research | Buy |
| May-20-25 | Upgrade | Piper Sandler | Neutral → Overweight |
| Mar-06-25 | Initiated | H.C. Wainwright | Buy |
| Jan-10-25 | Initiated | BTIG Research | Buy |
| May-12-23 | Downgrade | Piper Sandler | Overweight → Neutral |
| Aug-03-22 | Initiated | Jefferies | Buy |
View All
Immunitybio Inc Stock (IBRX) Latest News
INVESTOR DEADLINE TUESDAY: ImmunityBio, Inc. (IBRX) Investors with Substantial Losses Have Opportunity to Lead Class Action LawsuitRGRD Law – Company AnnouncementFT.com - Financial Times
ImmunityBio, Inc. Securities Fraud Class Action Result of FDA Warning and 21% Stock DeclineInvestors may Contact Lewis Kahn, Esq, at Kahn Swick & Foti, LLC - TMX Newsfile
ImmunityBio secures five US patents for Anktiva in bladder cancer - MSN
INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in ImmunityBio, Inc. Of Class Action Lawsuit and Upcoming DeadlinesIBRX - PR Newswire
ImmunityBio Shareholder Alert: ClaimsFiler Reminds - GlobeNewswire
IBRX Stock Drops As FDA Warning Triggers Class Actions - timothysykes.com
IBRX Investors Have Opportunity to Lead ImmunityBio, Inc. Securities Fraud Lawsuit with the ... - Caledonian Record
IBRX Investors Have Opportunity to Lead ImmunityBio, Inc. Securities Fraud Lawsuit with the Schall Law Firm - GlobeNewswire
IBRX EQUITY ACTION REMINDER: Faruqi & Faruqi, LLP Reminds ImmunityBio (IBRX) Investors of Securities Class Action Deadline on May 26, 2026 - PR Newswire
ImmunityBio (IBRX) Facing Lawsuit After FDA Flags Misleading Cancer Claims, Shares Plunge 21%, $2B Market Cap Lost -- HBSS - PR Newswire
ImmunityBio stock (US45258J1025): FDA accepts ANKTIVA bladder cancer filing and sets 2027 PDUFA date - AD HOC NEWS
IBRX 6-DAY DEADLINE ALERT: ImmunityBio (IBRX) Investors Face Losses Amid FDA Warning Regarding Unsupported Cancer Treatment Claims -- Hagens Berman - marketscreener.com
Assessing ImmunityBio (IBRX) Valuation After FDA Approval For Anktiva And Share Price Cooldown - Yahoo Finance
ImmunityBio: Could Be One Approval Away From A Multi-Billion Dollar Breakout - Seeking Alpha
Bronstein, Gewirtz & Grossman LLC Urges ImmunityBio, Inc. Investors to Act: Class Action Filed Alleging Investor Harm - GlobeNewswire Inc.
Why ImmunityBio Stock is Soaring Higher Today - Yahoo Finance
TAT Technologies Posts Upbeat Q1 Earnings, Joins Roivant Sciences, Immunitybio And Other Big Stocks Movin - Benzinga
FDA Accepts IBRX's Filing Seeking Expanded Use of Bladder Cancer Therapy - Yahoo Finance
ImmunityBio’s FDA Deadline Could Change Its Bladder-Cancer Story—But the Risk Is Still There - TechStock²
ImmunityBio stock surges as FDA accepts bladder cancer filing - Investing.com
IMMUNITYBIO, INC. INVESTORS WITH LOSSES HAVE UNTIL MAY 26, - GlobeNewswire
IBRX Reiterated by HC Wainwright & Co. -- Price Target Maintained at $15 - GuruFocus
ImmunityBio rises as Anktiva label expansion undergoes FDA review - Seeking Alpha
S&P 500 Futures Rise In Premarket Trading; Immunovant, ImmunityBio Lead - Moomoo
symbol__ Stock Quote Price and Forecast - CNN
FDA accepts ImmunityBio’s application for Anktiva expansion By Investing.com - Investing.com Nigeria
ImmunityBio Announces FDA Acceptance of Supplemental BLA for ANKTIVA® Plus BCG in BCG-Unresponsive N - PharmiWeb.com
ImmunityBio, Inc. Securities Fraud Class Action Result of - GlobeNewswire
IBRX Stock Jumps Overnight After Major FDA Review Win For Anktiva In Bladder Cancer - Stocktwits
ImmunityBio, Inc. announced that the U.S. Food and Drug Administration (FDA) has accepted its supplemental Biologics License Application (sBLA) for Anktiva® (nogapendekin alfa inbakicept) in combination with BCG for the treatment of BCG-unresponsive n - Bitget
FDA sets Jan. 6, 2027 for drug that helped patients avoid bladder removal - Stock Titan
FDA accepts ImmunityBio’s application for Anktiva expansion - Investing.com
ImmunityBio Announces FDA Acceptance of Supplemental BLA for ANKTIVA® Plus BCG in BCG-Unresponsive Non-Muscle Invasive Bladder Cancer with Papillary Disease; PDUFA Date Set for January 6, 2027 - Yahoo Finance
IBRX Stock’s Decline Makes Retail See ‘Incredible’ Buying Opportunity After Anktiva + BCG Therapy Delivered Favorable Results - Stocktwits
IBRX SHAREHOLDER NOTICE: Faruqi & Faruqi, LLP Reminds ImmunityBio (IBRX) Investors of Securities Class Action Deadline on May 26, 2026 - marketscreener.com
IBRX DEADLINE: ROSEN, RECOGNIZED INVESTOR COUNSEL, Encourages ImmunityBio, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action First Filed by the FirmIBRX - TMX Newsfile
ImmunityBio, Inc. (IBRX) Shareholders Who Lost Money Have Opportunity to Lead Securities Fraud Lawsuit - PR Newswire
ImmunityBio Says ANKTIVA Combo Outperformed Rival Bladder Cancer Therapies - Benzinga
ImmunityBio Secures Five U.S. Patents for Anktiva in Bladder Cancer - Yahoo Finance
ImmunityBio: Looking Beyond Bladder Cancer To A Multibillion-Dollar Solid Tumor TAM (IBRX) - Seeking Alpha
Portnoy Law Firm Announces Class Action on Behalf of ImmunityBio, Inc. Investors - GlobeNewswire
IBRX stock slips overnight: Founder teases Turkey push, says AI cancer cell robot is ‘almost there’ - MSN
ImmunityBio Presents Favorable Comparative Effectiveness Data in Complete Response Rates of NAI + BCG Versus Nadofaragene and TAR-200 at AUA 2026 - Business Wire
ImmunityBio Expands Bladder Cancer Arsenal With Exclusive Japanese BCG Partnership - Yahoo Finance
ImmunityBio Secures Exclusive U.S. Agreement to Supply Tokyo Strain BCG, Aiming to Resolve Bladder Cancer Treatment Shortage - Minichart
Key facts: ImmunityBio Wins Five US Patents for Anktiva; US Supply Deal - TradingView
ImmunityBio Secures Exclusive US Rights To Tokyo Strain BCG To Address Chronic Bladder Cancer Treatment Shortage - BioPharma APAC
ImmunityBio Secures Exclusive Tokyo-172 BCG Rights in U.S. - TipRanks
IMMUNITYBIO CLASS ACTION ALERT: Bragar Eagel & Squire, P.C. - GlobeNewswire
ImmunityBio Secures Exclusive U.S. Rights to Tokyo-172 BCG in Supply Pact With Japan BCG Laboratory - TradingView
Exclusive Tokyo BCG supply deal expands ImmunityBio (NASDAQ: IBRX) options - Stock Titan
Immunitybio Inc Stock (IBRX) Financials Data
Revenue
Net Income
Cash Flow
EPS
4.72%
0.63%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):